Inactive Instrument

Highlights Ligand Pharmaceuticals Inc. OTC Bulletin Board

Equities

US53220K1815

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

Jun. 18	Merck Receives FDA Approval for Capvaxive, Triggers $2 Million Payment for Ligand Pharmaceuticals	MT
Jun. 18	Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE? (Pneumococcal 21-valent Conjugate Vaccine) for Adults	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Merck Receives FDA Approval for Capvaxive, Triggers $2 Million Payment for Ligand Pharmaceuticals	Jun. 18	MT
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE? (Pneumococcal 21-valent Conjugate Vaccine) for Adults	Jun. 18	CI
Sector Update: Health Care Stocks Softer Late Afternoon	May. 08	MT
Ligand Pharmaceuticals Shares Rise After Q1 Adjusted Earnings, Revenue Beat Views	May. 08	MT
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Posts Q1 Revenue $31M, vs. Street Est of $27.9M	May. 07	MT
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q1 EPS $1.20, vs. Street Est of $0.83	May. 07	MT
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Ligand Pharmaceuticals Incorporated Reaffirms Earnings Guidance for the Year 2024	May. 07	CI
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading	May. 07	MT
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	May. 07	MT
Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference	Apr. 08	CI
Ligand Pharmaceuticals Appoints Scott Plesha to the Role of Chief Executive Officer for Pelthos Therapeutics	Apr. 03	CI
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics	Apr. 02	CI
Ligand Pharmaceuticals' Q4 Adjusted Earnings Rise, Revenue Falls; Reaffirms 2024 Guidance	Feb. 27	MT
Ligand Pharmaceuticals Incorporated Re-Affirms Earnings Guidance for 2024	Feb. 27	CI
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q4 Revenue $28.1M, vs. Street Est of $25.7M	Feb. 27	MT
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q4 EPS $1.05, vs. Street Est of $0.66	Feb. 27	MT
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
Global markets live: Merck, Honda, Novartis, Boeing, Nvidia...	Jan. 08
Ligand Pharmaceuticals Secures FDA Approval for Viral Skin Infection Medication; Shares Jump Premarket	Jan. 08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ligand Pharmaceuticals Inc. OTC Bulletin Board

Equities

US53220K1815

Highlights

Filters